Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer

Frank Weinberg, Shirish GadgeelDivision of Hematology and Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI, USAAbstract: Until recently, the treatment of patients with advanced non-small-cell lung cancer (NSCLC) whose tumors did not have a targetable genetic alteration was cyt...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Weinberg F, Gadgeel S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	NSCLC immunotherapy chemotherapy clinical trials Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/449832ce898049848b3bf1a0e69f940c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:449832ce898049848b3bf1a0e69f940c
record_format	dspace
spelling	oai:doaj.org-article:449832ce898049848b3bf1a0e69f940c2021-12-02T03:55:52ZCombination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer1179-2728https://doaj.org/article/449832ce898049848b3bf1a0e69f940c2019-06-01T00:00:00Zhttps://www.dovepress.com/combination-pembrolizumab-plus-chemotherapy-a-new-standard-of-care-for-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Frank Weinberg, Shirish GadgeelDivision of Hematology and Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI, USAAbstract: Until recently, the treatment of patients with advanced non-small-cell lung cancer (NSCLC) whose tumors did not have a targetable genetic alteration was cytotoxic chemotherapy alone. This treatment provided only modest survival benefit. The introduction of immune checkpoint inhibitors targeting programmed cell death 1 protein (PD-1) signaling pathway in the treatment of patients with NSCLC has had significant effect on patient survival. Atezolizumab, nivolumab and pembrolizumab have been shown to be superior to chemotherapy in patients with recurrent NSCLC. Recently, pembrolizumab has been combined with chemotherapy in the front-line setting and has demonstrated an improvement in overall survival in NSCLC patients as compared to chemotherapy alone. In this review we will focus on the clinical trials that led to approval of combination pembrolizumab and chemotherapy as first-line treatment for patients with advanced NSCLC as well as discuss other combinations of immunotherapy and chemotherapy that have also been evaluated.Keywords: NSCLC, immunotherapy, chemotherapy, clinical trialsWeinberg FGadgeel SDove Medical PressarticleNSCLCimmunotherapychemotherapyclinical trialsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 10, Pp 47-56 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	NSCLC immunotherapy chemotherapy clinical trials Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	NSCLC immunotherapy chemotherapy clinical trials Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Weinberg F Gadgeel S Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer
description	Frank Weinberg, Shirish GadgeelDivision of Hematology and Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI, USAAbstract: Until recently, the treatment of patients with advanced non-small-cell lung cancer (NSCLC) whose tumors did not have a targetable genetic alteration was cytotoxic chemotherapy alone. This treatment provided only modest survival benefit. The introduction of immune checkpoint inhibitors targeting programmed cell death 1 protein (PD-1) signaling pathway in the treatment of patients with NSCLC has had significant effect on patient survival. Atezolizumab, nivolumab and pembrolizumab have been shown to be superior to chemotherapy in patients with recurrent NSCLC. Recently, pembrolizumab has been combined with chemotherapy in the front-line setting and has demonstrated an improvement in overall survival in NSCLC patients as compared to chemotherapy alone. In this review we will focus on the clinical trials that led to approval of combination pembrolizumab and chemotherapy as first-line treatment for patients with advanced NSCLC as well as discuss other combinations of immunotherapy and chemotherapy that have also been evaluated.Keywords: NSCLC, immunotherapy, chemotherapy, clinical trials
format	article
author	Weinberg F Gadgeel S
author_facet	Weinberg F Gadgeel S
author_sort	Weinberg F
title	Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer
title_short	Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer
title_full	Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer
title_fullStr	Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer
title_full_unstemmed	Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer
title_sort	combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/449832ce898049848b3bf1a0e69f940c
work_keys_str_mv	AT weinbergf combinationpembrolizumabpluschemotherapyanewstandardofcareforpatientswithadvancednonsmallcelllungcancer AT gadgeels combinationpembrolizumabpluschemotherapyanewstandardofcareforpatientswithadvancednonsmallcelllungcancer
_version_	1718401545436921856

Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer

Ejemplares similares